Govind Srimathveeravalli

547 posts

Govind Srimathveeravalli

Govind Srimathveeravalli

@GovindSLab

first of my name, father of unicorns, bane of cancer cells, lord of lightning, maker of healing devices and teacher of design. Assoc Prof at UMass Amherst.

Massachusetts, USA Katılım Kasım 2019
284 Takip Edilen185 Takipçiler
Govind Srimathveeravalli retweetledi
Dr. Anthony Letai
Dr. Anthony Letai@NCIDirector·
I’ve heard concerns about @theNCI funding in FY26—especially about the number of awards issued so far. Here’s some context. 🧵
English
2
18
98
26.7K
Govind Srimathveeravalli
Govind Srimathveeravalli@GovindSLab·
@JuliusChapiro Most medical components are built on top of standard/industrial gas/liquid handling ones. McMaster or similar may have tubing that you can repurpose “off label”
English
1
0
2
147
Julius Chapiro
Julius Chapiro@JuliusChapiro·
Supply chain help request to the IR community: we are extremely short on the CO2 injection tubing, which is on backorder. Despite numerous attempts, we seem unable to find replacements. My supply chain guy asked me to share this and ask if y’all know any suppliers that have this or similar in stock? Anybody know anything?
Julius Chapiro tweet media
English
3
0
3
1.3K
Govind Srimathveeravalli retweetledi
Julius Chapiro
Julius Chapiro@JuliusChapiro·
Courageous and great article from @MSKCancerCenter on Histotripsy published in @cvironco ! Link: link.springer.com/article/10.100… “Patients arrive with predetermined expectations shaped by marketing rather than clinical reality, pressuring physicians to offer treatments lacking comprehensive validation. Healthcare institutions acquire expensive systems to remain competitive, even when clinical need may not justify the investment. Resources are diverted toward technologies with limited proven benefit, while established treatments receive diminished attention.” “Aggressive promotion, driven by commercial interests and capital market pressures, presents theoretical benefits as established advantages. Current histotripsy studies remain predominantly single-center experiences with limited follow-up. The technology’s purported immunologic effects remain entirely theoretical, yet marketing materials present these claims with inappropriate certainty. Patients seek "non-invasive" treatments based on promotional materials overstating capabilities while minimising limitations. This marketing-first approach raises ethical concerns about informed consent and resource allocation.”
Julius Chapiro tweet media
English
5
10
47
12.4K
Ali Khademhosseini
Ali Khademhosseini@khademh·
After an incredible journey at the Terasaki Institute, I'm excited to announce that I'm stepping into a new chapter focused on entrepreneurship at the intersection of AI and real-world impact. Over the past few years, I've found myself increasingly captivated by the transformative potential of artificial intelligence. What started as curiosity has evolved into a deep conviction about AI's capacity to reshape how we approach fundamental challenges. I've immersed myself fully in understanding not just the technology itself, but how we can harness it to create meaningful change in the world. I believe we're at an inflection point where AI can unlock solutions that were previously out of reach, and I'm thrilled to be part of pushing these boundaries forward. I've already begun this entrepreneurial journey and am energized by what's ahead. I'll be sharing more updates as things develop, and I'm looking forward to building something transformative. For anyone interested in connecting about AI, entrepreneurship, or potential collaborations, please feel free to DM me. I'm always eager to connect with others who share this passion for leveraging technology to make a difference. Here's to new beginnings and the exciting challenges ahead!
English
3
3
40
4.8K
Govind Srimathveeravalli
Govind Srimathveeravalli@GovindSLab·
@drugmonkeyblog Been tracking this data for nci. Majority of recent ones are single year awards. Is there any way of parsing what payline and council dates are being funded?
English
1
0
0
254
Govind Srimathveeravalli
Govind Srimathveeravalli@GovindSLab·
@drugmonkeyblog I read these with great (self interest). I was tracking some of this for NCI. It appears many multi year awards went to ECI. Based on numbers, there’s should be considerable unspent funds remaining with 6 weeks in the FY.
English
0
1
1
515
Govind Srimathveeravalli
Govind Srimathveeravalli@GovindSLab·
@BladderCancerUS I did go through the criteria. It did not seem my case was a good fit, I wanted to know if an exception could be made. An email to the contact on the site did not elicit any useful guidance. Ergo the public post on Twitter - which advised me to go read the rfa.
English
1
0
0
17
PIGILab
PIGILab@PigiLab·
Introducing The Kim Lab for Innovation in Image Guided Interventions! 🚨 State of the art technology with ground breaking science. Small and large animal research, device development, industry collaborations, and AR/VR deployment. @PennMedicine @PennRadiology
English
1
5
16
1.3K
Uber India Support
Uber India Support@UberIN_Support·
@GovindSLab Hi there, this is definitely not the kind of experience we would like you to have. Please send across your registered details via Direct Message, we'll get this addressed at the earliest.
English
1
0
0
18
Govind Srimathveeravalli
Govind Srimathveeravalli@GovindSLab·
@Uber_India wanted to share feedback on a recent trip but the app is restricted on options. Driver showed up just short of the spot, changed status to arrived but kept playing tag when we tried getting into the car. Uber automatically rebooked another taxi.
English
3
0
0
81
Govind Srimathveeravalli
Govind Srimathveeravalli@GovindSLab·
Driver then stops for pick up and asks me to cancel the other ride as he can take me to destination. When I boarded asked me to pay cash for the original amount. As uber only allows feedback for completed rides, there’s no way of providing feedback on this person with app. #scam
English
0
0
0
144
Michael Koeris
Michael Koeris@mkoeris·
At @DARPA’s BTO, our mission is to harness biology for national security, from AI-driven protein design to synthetic biology that redefines resilience. Spicy Monday take: If we’re not making our adversaries think twice (or three times!) about getting at us, we’re not meeting the mission! Anticipate and create surprise! That’s the mission. 🫡🇺🇸 What’s the craziest idea you got on a Monday?
English
1
0
5
454
Govind Srimathveeravalli
Govind Srimathveeravalli@GovindSLab·
@abandopa I am not in India but am very much involved in medtech startups here. Would love to be part of this for. Please let me know if I can join.
English
1
0
0
62
Amitabha Bandyopadhy
Amitabha Bandyopadhy@abandopa·
I am trying to build a WhatsApp Community for MedTech startups and ecosystem enablers. If you are one of these brave Indians, will you be kind enough to share your WhatsApp contact with me? I will take the responsibility of ensuring that it remains a strictly professional group.
English
31
42
103
16.2K
Govind Srimathveeravalli
Govind Srimathveeravalli@GovindSLab·
@draparente @eric_is_weird I like doing the research and literature reviews. I can go down interesting rabbit holes and make connections that go beyond the query. Filling paperwork, placing orders, generating annual reports, writing protocols and answer emails would free up so much of my productive time
English
0
0
0
34
Angelica Parente
Angelica Parente@draparente·
Say this all the time - ops/admin could be initial use cases. If there was a tool that let PIs be PIs that would be extremely impactful for scientific productivity and student training. What areas do you think would be most impactful? - RFA scouting - grant progress report support (eg generate reports from data PowerPoints) - anything for study sections? - administrative forms and reporting automation, due date tracking, etc
English
1
0
0
22
Eric Gilliam
Eric Gilliam@eric_is_weird·
If somebody gave a founder ~10 years of runway and $2 million/year to continually build + deploy tools that made LLMs increasingly essential in Cambridge, MA academic labs, what would you build?
English
11
3
30
5.9K